Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.
2.

Contributions of Thyroid Hormone to Cancer Metastasis.

Mousa SA, Glinsky GV, Lin HY, Ashur-Fabian O, Hercbergs A, Keating KA, Davis PJ.

Biomedicines. 2018 Aug 22;6(3). pii: E89. doi: 10.3390/biomedicines6030089. Review.

4.
5.

Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation.

Srinivasan M, Bharali DJ, Sudha T, Khedr M, Guest I, Sell S, Glinsky GV, Mousa SA.

Oncotarget. 2017 Jun 13;8(24):38731-38742. doi: 10.18632/oncotarget.16317.

7.

Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.

Glinsky GV.

Cancer Lett. 2016 Oct 10;381(1):176-93. doi: 10.1016/j.canlet.2016.08.001. Epub 2016 Aug 3.

PMID:
27497790
8.

Actions of Thyroid Hormone Analogues on Chemokines.

Davis PJ, Glinsky GV, Lin HY, Mousa SA.

J Immunol Res. 2016;2016:3147671. doi: 10.1155/2016/3147671. Epub 2016 Jul 17. Review.

9.

Activation of endogenous human stem cell-associated retroviruses (SCARs) and therapy-resistant phenotypes of malignant tumors.

Glinsky GV.

Cancer Lett. 2016 Jul 1;376(2):347-59. doi: 10.1016/j.canlet.2016.04.014. Epub 2016 Apr 12. Review.

PMID:
27084523
11.

Corrigendum: "Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac".

Davis PJ, Glinsky GV, Lin HY, Leith JT, Hercbergs A, Tang HY, Ashur-Fabian O, Incerpi S, Mousa SA.

Front Endocrinol (Lausanne). 2015 Jun 9;6:98. doi: 10.3389/fendo.2015.00098. eCollection 2015.

12.

Thyroid hormone and anti-apoptosis in tumor cells.

Lin HY, Glinsky GV, Mousa SA, Davis PJ.

Oncotarget. 2015 Jun 20;6(17):14735-43. Review.

14.

Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac.

Davis PJ, Glinsky GV, Lin HY, Leith JT, Hercbergs A, Tang HY, Ashur-Fabian O, Incerpi S, Mousa SA.

Front Endocrinol (Lausanne). 2015 Jan 12;5:240. doi: 10.3389/fendo.2014.00240. eCollection 2014. Review. Erratum in: Front Endocrinol (Lausanne). 2015;6:98.

15.

Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.

Zhang H, Cohen AL, Krishnakumar S, Wapnir IL, Veeriah S, Deng G, Coram MA, Piskun CM, Longacre TA, Herrler M, Frimannsson DO, Telli ML, Dirbas FM, Matin AC, Dairkee SH, Larijani B, Glinsky GV, Bild AH, Jeffrey SS.

Breast Cancer Res. 2014 Apr 7;16(2):R36. doi: 10.1186/bcr3640.

16.

An on-demand four-way junction DNAzyme nanoswitch driven by inosine-based partial strand displacement.

Mo AH, Landon PB, Meckes B, Yang MM, Glinsky GV, Lal R.

Nanoscale. 2014;6(3):1462-6. doi: 10.1039/c3nr05365b.

PMID:
24317092
17.
18.

Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response.

Davis PJ, Glinsky GV, Lin HY, Incerpi S, Davis FB, Mousa SA, Tang HY, Hercbergs A, Luidens MK.

Endocr Res. 2013;38(2):112-8. doi: 10.3109/07435800.2013.778865. Review.

PMID:
23545000
19.

Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine.

Glinskii OV, Sud S, Mossine VV, Mawhinney TP, Anthony DC, Glinsky GV, Pienta KJ, Glinsky VV.

Neoplasia. 2012 Jan;14(1):65-73.

20.

Networks of intergenic long-range enhancers and snpRNAs drive castration-resistant phenotype of prostate cancer and contribute to pathogenesis of multiple common human disorders.

Glinskii AB, Ma S, Ma J, Grant D, Lim CU, Guest I, Sell S, Buttyan R, Glinsky GV.

Cell Cycle. 2011 Oct 15;10(20):3571-97. doi: 10.4161/cc.10.20.17842.

22.

Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid.

Yalcin M, Dyskin E, Lansing L, Bharali DJ, Mousa SS, Bridoux A, Hercbergs AH, Lin HY, Davis FB, Glinsky GV, Glinskii A, Ma J, Davis PJ, Mousa SA.

J Clin Endocrinol Metab. 2010 Apr;95(4):1972-80. doi: 10.1210/jc.2009-1926. Epub 2010 Feb 4.

PMID:
20133461
23.
24.

Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac).

Glinskii AB, Glinsky GV, Lin HY, Tang HY, Sun M, Davis FB, Luidens MK, Mousa SA, Hercbergs AH, Davis PJ.

Cell Cycle. 2009 Nov 1;8(21):3562-70. Epub 2009 Nov 1.

PMID:
19838061
25.

Real-time case fatality analysis points to emerging evidence of increasing severity of pandemic (H1N1) 2009.

Glinsky GV.

Cell Cycle. 2009 Oct 1;8(19):3057-62. Epub 2009 Oct 16. No abstract available.

PMID:
19755847
26.

Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo.

Glinsky VV, Kiriakova G, Glinskii OV, Mossine VV, Mawhinney TP, Turk JR, Glinskii AB, Huxley VH, Price JE, Glinsky GV.

Neoplasia. 2009 Sep;11(9):901-9.

27.

Human genome connectivity code links disease-associated SNPs, microRNAs and pyknons.

Glinsky GV.

Cell Cycle. 2009 Mar 15;8(6):925-30. Epub 2009 Mar 26.

PMID:
19229130
28.

Quantitative analysis of circulating tumor cells as a survival predictor in metastatic castration-resistant prostate cancer: missing parts in a superb study.

Glinsky GV.

Clin Cancer Res. 2009 Feb 15;15(4):1504; 1504-5. doi: 10.1158/1078-0432.CCR-08-2580. No abstract available.

29.
31.

Regenerative medicine: clinical relevance, implications and limitations of the stem cell-based therapies.

Glinsky GV.

Cell Cycle. 2008 Nov 1;7(21):3292-3. Epub 2008 Nov 11. No abstract available.

PMID:
18948738
32.

Regenerative medicine: evidence for remarkable healing power of adult (somatic) stem cells.

Glinsky GV.

Cell Cycle. 2008 Jun 15;7(12):1697. Epub 2008 Jun 15. No abstract available.

PMID:
18728405
33.

Remarkable features of tiny RNA molecules: highlights of revolutionary discoveries on the path from the bench to bedside.

Glinsky GV.

Cell Cycle. 2008 Aug 15;7(16):2451. Epub 2008 Aug 15. No abstract available.

PMID:
18719381
35.

Emerging genomic technologies and the concept of personalized medicine.

Glinskii VG, Glinsky GV.

Cell Cycle. 2008 Aug;7(15):2278-85. Epub 2008 Jun 23.

PMID:
18677102
36.

"Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.

Glinsky GV.

J Clin Oncol. 2008 Jun 10;26(17):2846-53. doi: 10.1200/JCO.2008.17.0266. Review.

PMID:
18539963
37.

Phenotype-defining functions of multiple non-coding RNA pathways.

Glinsky GV.

Cell Cycle. 2008 Jun 1;7(11):1630-9. Epub 2008 Mar 19.

PMID:
18469518
38.

Stem cell origin of death-from-cancer phenotypes of human prostate and breast cancers.

Glinsky GV.

Stem Cell Rev. 2007 Jan;3(1):79-93. Review.

PMID:
17873385
39.

Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia.

Johnson KD, Glinskii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC, Henry CJ, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV.

Neoplasia. 2007 Aug;9(8):662-70.

40.

Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation.

Mawji IA, Simpson CD, Hurren R, Gronda M, Williams MA, Filmus J, Jonkman J, Da Costa RS, Wilson BC, Thomas MP, Reed JC, Glinsky GV, Schimmer AD.

J Natl Cancer Inst. 2007 May 16;99(10):811-22.

PMID:
17505076
42.

Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.

Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV.

Cell Cycle. 2006 Aug;5(16):1886-901. Epub 2006 Aug 15.

PMID:
16963837
44.

Dual-color-coded imaging of viable circulating prostate carcinoma cells reveals genetic exchange between tumor cells in vivo, contributing to highly metastatic phenotypes.

Glinsky GV, Glinskii AB, Berezovskaya O, Smith BA, Jiang P, Li XM, Yang M, Hoffman RM.

Cell Cycle. 2006 Jan;5(2):191-7. Epub 2006 Jan 16.

PMID:
16357534
45.

Death-from-cancer signatures and stem cell contribution to metastatic cancer.

Glinsky GV.

Cell Cycle. 2005 Sep;4(9):1171-5. Epub 2005 Sep 11. Review.

PMID:
16082216
46.

Identification of genes associated with tumor progression using microarrays.

Gebauer G, Krones-Herzig A, Glinskii AB, Glinsky GV.

Anticancer Res. 2005 May-Jun;25(3A):1477-82.

47.

Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs.

Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV.

Neoplasia. 2005 May;7(5):522-7.

48.
49.

Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells.

Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC, Glinsky GV.

Cancer Res. 2005 Mar 15;65(6):2378-86.

50.

Supplemental Content

Loading ...
Support Center